Enterprise Value

199.6M

Cash

548.9M

Avg Qtr Burn

-46.04M

Short % of Float

6.90%

Insider Ownership

9.91%

Institutional Own.

79.53%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Latozinemab (AL001) (progranulin) Details
Frontotemporal dementia with a granulin mutation, Dementia

Phase 3

Data readout

AL101 (GSK4527226) (Progranulin) Details
Parkinson's disease, Alzheimer's disease, Neurological disorder

Phase 2

Data readout

AL002 (TREM 2) Details
Alzheimer's disease

Phase 2

Data readout

Latozinemab (AL001) (progranulin) Details
Frontotemporal dementia with C9orf72 mutation, Dementia, Amyotrophic lateral sclerosis

Phase 2

Update

AL003 (SIGLEC 3) Details
Alzheimer's disease

Failed

Discontinued